Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Elapegademase-lvlr
2. Revcovi
1. Revcovi
2. Elapegademase-lvlr
3. Elapegademase [inn]
4. Unii-9r3d3y0uhs
5. Elapegademase [usan:inn]
6. 9r3d3y0uhs
7. Schembl20670726
8. Ezn-2279
9. Q27272923
10. 1709806-75-6
11. Poly(oxy-1,2-ethanediyl), Alpha-carboxy-omega-methoxy-, Amide With Adenosine Deaminase (synthetic)
Molecular Weight | 248.28 g/mol |
---|---|
Molecular Formula | C10H20N2O5 |
XLogP3 | -2.7 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 10 |
Exact Mass | 248.13722174 g/mol |
Monoisotopic Mass | 248.13722174 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 235 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Elapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. This condition was previously treated by the use of bovine pegamedase as part of an enzyme replacement therapy. ADA-SCID is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme. The patients suffering from this disease often present with a compromised immune system. This condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infections.
FDA Label
In clinical trials, elapegademase was shown to increase adenosine deaminase activity while reducing the concentrations of toxic metabolites which are the hallmark of ADA-SCID. As well, it was shown to improve the total lymphocyte count.
Adenosine Deaminase Inhibitors
Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)
L - Antineoplastic and immunomodulating agents
L03 - Immunostimulants
L03A - Immunostimulants
L03AX - Other immunostimulants
L03AX21 - Elapegademase
Absorption
Elapegademase is administered intramuscularly and the reported Tmax, Cmax and AUC are approximately 60 hours, 240 mmol.h/L and 33000 hr.mmol/L as reported during a week.
Route of Elimination
This pharmacokinetic property has not been fully studied.
Volume of Distribution
This pharmacokinetic property has not been fully studied.
Clearance
This pharmacokinetic property has not been fully studied.
Metabolism studies have not been performed but it is thought to be degraded by proteases to small peptides and individual amino acids.
This pharmacokinetic property has not been fully studied.
The ADA-SCID is caused by the presence of mutations in the ADA gene which is responsible for the synthesis of adenosine deaminase. This enzyme is found throughout the body but it is mainly active in lymphocytes. The normal function of adenosine deaminase is to eliminate deoxyadenosine, created when DNA is degraded, by converting it into deoxyinosine. This degradation process is very important as deoxyadenosine is cytotoxic, especially for lymphocytes. Immature lymphocytes are particularly vulnerable as deoxyadenosine kills them before maturation making them unable to produce their immune function. Therefore, based on the causes of ADA-SCID, elapegademase works by supplementing the levels of adenosine deaminase. Being a recombinant and an _E. coli_-produced molecule, the use of this drug eliminates the need to source the enzyme from animals, as it was previously.
Global Sales Information
ABOUT THIS PAGE
A Elapegademase manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elapegademase, including repackagers and relabelers. The FDA regulates Elapegademase manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elapegademase API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Elapegademase supplier is an individual or a company that provides Elapegademase active pharmaceutical ingredient (API) or Elapegademase finished formulations upon request. The Elapegademase suppliers may include Elapegademase API manufacturers, exporters, distributors and traders.
click here to find a list of Elapegademase suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Elapegademase Drug Master File in Japan (Elapegademase JDMF) empowers Elapegademase API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Elapegademase JDMF during the approval evaluation for pharmaceutical products. At the time of Elapegademase JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Elapegademase suppliers with JDMF on PharmaCompass.
Elapegademase Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Elapegademase GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elapegademase GMP manufacturer or Elapegademase GMP API supplier for your needs.
A Elapegademase CoA (Certificate of Analysis) is a formal document that attests to Elapegademase's compliance with Elapegademase specifications and serves as a tool for batch-level quality control.
Elapegademase CoA mostly includes findings from lab analyses of a specific batch. For each Elapegademase CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Elapegademase may be tested according to a variety of international standards, such as European Pharmacopoeia (Elapegademase EP), Elapegademase JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elapegademase USP).
LOOKING FOR A SUPPLIER?